PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26099922-1	2015	BACKGROUND: Halofuginone (HF) is a low-molecular-weight alkaloid that has been demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-beta (TGF-beta) function and, to present antiangiogenic, antiproliferative and proapoptotic properties in several solid tumor models.	halofuginone	12-24	matrix metallopeptidase 2	Mus musculus	131-136	
11099465-1	2000	We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression.	halofuginone	37-49	matrix metallopeptidase 2	Mus musculus	146-172	
11099465-1	2000	We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression.	halofuginone	37-49	matrix metallopeptidase 2	Mus musculus	174-179	
10463616-1	1999	We have previously demonstrated that halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 gene expression.	halofuginone	37-49	matrix metallopeptidase 2	Mus musculus	136-162	
15177499-1	2004	Halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha 1 (I) and matrix metalloproteinase 2 gene expression.	halofuginone	0-12	matrix metallopeptidase 2	Mus musculus	101-127	
10473075-0	1999	Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.	halofuginone	88-100	matrix metallopeptidase 2	Mus musculus	14-40	
10473075-5	1999	We now report that expression of the MMP-2 gene by murine (MBT2-t50) and human (5637) bladder carcinoma cells is highly susceptible to inhibition by halofuginone.	halofuginone	149-161	matrix metallopeptidase 2	Mus musculus	37-42	
10473075-7	1999	This inhibition is due to an effect of halofuginone on the activity of the MMP-2 promoter, as indicated by a pronounced suppression of chloramphenicol acetyltransferase activity driven by the MMP-2 promoter in transfected MBT2 cells.	halofuginone	39-51	matrix metallopeptidase 2	Mus musculus	75-80	
10473075-7	1999	This inhibition is due to an effect of halofuginone on the activity of the MMP-2 promoter, as indicated by a pronounced suppression of chloramphenicol acetyltransferase activity driven by the MMP-2 promoter in transfected MBT2 cells.	halofuginone	39-51	matrix metallopeptidase 2	Mus musculus	192-197	
10473075-9	1999	Halofuginone-treated cells failed to invade through reconstituted basement-membrane (Matrigel) coated filters, in accordance with the inhibition of MMP-2 gene expression.	halofuginone	0-12	matrix metallopeptidase 2	Mus musculus	148-153	
10473075-13	1999	These results indicate that the potent antimetastatic activity of halofuginone is due primarily to a transcriptional suppression of the MMP-2 gene, which results in a decreased enzymatic activity, matrix degradation, and tumor cell extravasation.	halofuginone	66-78	matrix metallopeptidase 2	Mus musculus	136-141